This study examined a panel of 110 uk field isolates of feline calicivirus ( fcv ) for susceptibility to cross‐neutralisation by a panel of eight antisera raised in cats infected with fcv strains F9, 255, fcvg1 and fcv431 . The pairs of antisera raised against F9 or 255, neutralised 20 and 21 per cent or 37 and 56 per cent of field strains of virus respectively. In contrast, the pairs of antisera raised against the newer vaccine strains fcvg1 or fcv431 neutralised 29 and 70 per cent or 67 and 87 per cent of field strains respectively. Antisera raised against the two newer strains, namely fcvg1 and fcv431 , neutralised a greater proportion of field strains of calicivirus than antisera raised against the older fcv vaccine strains F9 and 255.
1 September 2020 in Journal of Microbiological Methods
Seven brands of veterinary rabies vaccines are commercially available in Sri Lanka, but there is no established procedure to test the potency of the vaccines at the local level, especially prior to their release. The aim of this study was to test the potency of these vaccines using a mouse challenge test in collaboration with the EU/WOAH/WHO Reference Laboratory for Rabies, ANSES-Nancy, France. Based on the European Pharmacopoeia, the inactivated rabies vaccines complied with the mouse potency test if the estimated potency is ≥1.0 IU in the smallest prescribed dose. Among the eight tested vaccines, four single-dose preparations (Rabisin™, Raksharab™, Nobivac™ RL, and Nobivac™ Rabies) were compliant, with potencies of 12 IU/dose, 7.2 IU/dose, 4.4 IU/dose, and 3.4 IU/dose, respectively. Three of the single-dose preparations (Canvac™ R, Defensor™ 3, and Rabies killed vaccine) were not compliant, with potency values <1.0 IU/dose. One multidose preparation (Raksharab™ multidose) had a potency of 1.3 IU/dose, even though the test was not validated. Based on these results, it appears that some rabies vaccine batches that are currently available in the local market do not comply with the mouse potency test. Testing the vaccines’ potency before registration and release to the market appears to be an important step to allow good immunization to animals during pre-exposure vaccination programs.
1 January 2023 in Clinical and Experimental Vaccine Research
As part of the preparatory phase of a disease control programme in three herds infected with bovine virus diarrhoea-mucosal disease (BVD-MD) virus (demonstrated by virus isolation), initial serological screening was performed on all livestock older than six months (351 animals) by blocking enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody recognising a common epitope to the different strains of BVD-MD virus. The presence of immunotolerant, persistently-infected animals was strongly suspected, as a high percentage (334 = 95.2%) of cattle showed positive serological reactions, while the other members of the herd (17 = 4.8%) continued to give negative results, even after vaccination with a live vaccine. Whole blood samples from all cattle were then tested individually for viral antigen by an ELISA technique which had previously been tested successfully. As a result, a total of nine viraemic animals were identified in the three herds. A confirmatory test was performed by the reference amplification method on cell culture with virus identification using specific fluorescein isothiocyanate-labelled monoclonal antibodies. The identification and elimination of the persistently-infected animals led to the recovery of a negative serological status for the herds. It was therefore recommended that protective measures should be taken to avoid the reappearance of viraemic animals, involving vaccination and systematic viral testing before introducing any new animal into the herd. It was advisable that these measures should be maintained until all the potential reservoirs and vectors of BVD-MD virus are better known.
Leptospirosis is a widespread zoonosis caused by spirochaetes belonging to the pathogenic species of Leptospira, which are classified into more than 25 serogroups and 250 serovars. Vaccination can prevent the disease in dogs but offers incomplete efficacy because of a lack of cross-protection between serogroups. The aim of this study was to validate a robust recruitment and sampling process, with the objectives of isolating and typing circulating Leptospira pathogenic strains and then selecting those of proven virulence and pathogenicity for vaccine development. Blood and urine samples from dogs with clinical syndromes compatible with acute leptospirosis were sterilely collected and transported to a reference laboratory for a micro-agglutination test (MAT), PCR, and bacterial isolation. Isolated strains underwent molecular typing using RNA16S, variable-number tandem repeat (VNTR), and pulsed-field gel electrophoresis (PFGE). Subtyping was performed using core genome multilocus sequence typing (CgMLST). Among 64 included dogs, 41 had MAT and/or PCR results compatible with Leptospira infection, and 14 Leptospira strains were isolated. Based on molecular typing, 11 isolates were classified as L. interrogans serogroup Australis, serovar Bratislava, and 3 as serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae. CgMLST subtyping revealed a diversity of clonal groups (CGs) distributed in several regional clusters. Besides validating a robust recruitment and sampling process, this study outlines the value of combining PCR and serological testing when suspecting leptospirosis and the usefulness of implementing molecular typing methods to identify circulating field strains. It also confirms the epidemiological importance of the Australis serogroup and allows for the collection of different highly pathogenic strains for vaccine development.